The Relationship of Carotid Intima-Media Thickness with Cell Adhesion Molecules and Pentraxin-3 in Patients with Psoriatic Arthritis
暂无分享,去创建一个
S. Erdal | C. Ulman | T. Pırıldar | Ö. Soysal Gündüz | F. Can | Kezban Armağan Alptürker | Menice Güler Şen
[1] W. Schmidt,et al. Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial , 2021, Trials.
[2] C. Little,et al. Limited utility of novel serological biomarkers in patients newly suspected of having giant cell arteritis , 2021, International journal of rheumatic diseases.
[3] L. Coates,et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial , 2020, Annals of the Rheumatic Diseases.
[4] M. Tomšič,et al. The cut-off values for the intima-media complex thickness assessed by colour Doppler sonography in seven cranial and aortic arch arteries. , 2020, Rheumatology.
[5] Ş. Balta. Endothelial dysfunction and inflammatory markers of vascular disease. , 2020, Current vascular pharmacology.
[6] U. Fearon,et al. Enhanced angiogenic function in response to fibroblasts from psoriatic arthritis synovium compared to rheumatoid arthritis , 2019, Arthritis Research & Therapy.
[7] A. Mantovani,et al. Pentraxin 3 in Cardiovascular Disease , 2019, Front. Immunol..
[8] M. Hirata,et al. Relationship between circulating VCAM-1, ICAM-1, E-selectin and MMP9 and the extent of coronary lesions , 2018, Clinics.
[9] E. Kerzberg,et al. Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors , 2018, Front. Immunol..
[10] M. Chang,et al. Underestimation of Risk of Carotid Subclinical Atherosclerosis by Cardiovascular Risk Scores in Patients with Psoriatic Arthritis , 2017, The Journal of Rheumatology.
[11] E. Üstüner,et al. AB0762 The relationship between serum pentraxin-3 levels, cardiovascular disease risk and disease activity in psoriatic arthritis patients , 2017 .
[12] P. Krishan,et al. Atherosclerosis in Psoriatic Arthritis: A Multiparametric Analysis Using Imaging Technique and Laboratory Markers of Inflammation and Vascular Function , 2016, International Journal of Angiology.
[13] S. Doǧru-Abbasoǧlu,et al. Serum Visfatin, Fetuin‐A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity , 2016, Journal of clinical laboratory analysis.
[14] T. Kawada,et al. Metabolic syndrome showed significant relationship with carotid atherosclerosis , 2016, Heart and Vessels.
[15] S. Tas,et al. Targeting of proangiogenic signalling pathways in chronic inflammation , 2016, Nature Reviews Rheumatology.
[16] E. Tremoli,et al. Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies , 2015, Annals of medicine.
[17] F. Yilmaz,et al. The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis. , 2014, European review for medical and pharmacological sciences.
[18] M. Schoels. Psoriatic arthritis indices. , 2014, Clinical and experimental rheumatology.
[19] M. González-Gay,et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis , 2013, Annals of the rheumatic diseases.
[20] S. Arias-Santiago,et al. SAT0295 Comparison of subclinical carotid atherosclerosis in patients with psoriatic arthritis, psoriasis alone and controls , 2013 .
[21] M. Turiel,et al. Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Psoriatic Arthritis , 2011, The Journal of Rheumatology.
[22] C. Mok,et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. , 2011, Arthritis and rheumatism.
[23] L. Coates,et al. Development of a preliminary composite disease activity index in psoriatic arthritis , 2010, Annals of the rheumatic diseases.
[24] D. Veale,et al. Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis , 2010, The Journal of Rheumatology.
[25] M. Gobbi,et al. Regulation of leukocyte recruitment by the long pentraxin PTX3 , 2010, Nature Immunology.
[26] C. Garlanda,et al. Deficiency of the Long Pentraxin PTX3 Promotes Vascular Inflammation and Atherosclerosis , 2009, Circulation.
[27] L. Kuller,et al. Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause Death: The Cardiovascular Health Study , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[28] Cheuk-Man Yu,et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. , 2008, Arthritis and rheumatism.
[29] M. Dougados,et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate , 2008, Annals of the rheumatic diseases.
[30] Dafna Gladman,et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.
[31] B. Joffe,et al. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis , 2004, Arthritis research & therapy.
[32] S P McKenna,et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis , 2003, Annals of the rheumatic diseases.
[33] A. Calin,et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. , 1994, The Journal of rheumatology.
[34] A. Calin,et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.
[35] A Calin,et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. , 1994, The Journal of rheumatology.
[36] A. Finlay,et al. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.
[37] Özge Darka. Hücre Adezyon Molekülleri veEnflamasyondaki Rolleri , 2003 .
[38] P. Ridker. Novel risk factors and markers for coronary disease. , 2000, Advances in internal medicine.
[39] Ö. Saygili,et al. Hücre Adezyon Molekülleri , 1999 .
[40] H. Holman,et al. Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.
[41] T Fredriksson,et al. Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.
[42] W. Eyler,et al. PSORIATIC ARTHRITIS. , 1965, Henry Ford Hospital medical bulletin.